Cell & Gene Therapy Bioprocessing & Commercialization is back

That's right! It's that time again and Knect365 Life Sciences is getting geared up for the event which focuses on all phases across cell & gene therapy.

Go to the profile of RegMedNet
Aug 10, 2018

Bringing together 300+ leaders and key influencers from pharma and biotech companies on September 4-7 in Boston, Cell & Gene Therapy Bioprocessing & Commercializationwill provide you with the latest advice for driving manufacturing and commercialization through direct access to transforming innovative research to drive the future of cell & gene therapy manufacturing and commercialization.

Real-World Insights. Trusted Resources. Novel Solutions.

Discover everything you need in one place. Move between 4 streams jam packed with topical talks and industry case studies and meet with colleagues for an unrivalled on-site experience.

Highlights from this year’s meeting include:

  • 4 streams covered in 3 days:
    • Cell and Gene Therapy Bioprocessing
    • Cell Therapy Commercialization
    • Pre-clinical and Clinical Development for Cell and Gene Therapies
    • Logistics, Supply Chain, and Cryopreservation Techniques (NEW!)
    • Raw Materials Focus Day
    • Process Development and Manufacturing Scale Up for Engineered Tissues
    • Cell and Gene Connect – Partnering
  • More than 50+ speakers from top companies such as Novartis, Pluristem, bluebird bio, and Kite
  • In-depth panel discussions with well-renowned industry leaders
  • Cell & Gene Therapy Bioprocessing & Commercialization is co-located with BioProcess International as part of Biotech Week Boston, allowing you access to additional sessions as well as endless networking opportunities
  • Pre-Conference Workshops

Find out more out the event at www.CellGeneEvent.com

Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.